Product Center
Launch Ceremony of Tetravalent Influenza Virus Subunit Vaccine Huierkangxin Successfully Held!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26
- Views:
(Summary description)On September 25th, the launch ceremony of Ab&B Bio-Tech Co., Ltd. JS's tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
Launch Ceremony of Tetravalent Influenza Virus Subunit Vaccine Huierkangxin Successfully Held!
(Summary description)On September 25th, the launch ceremony of Ab&B Bio-Tech Co., Ltd. JS's tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26 10:00
- Views:
On September 25th, the launch ceremony of Ab&B Bio-Tech Co., Ltd. JS's tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
At the ceremony, Mr. An Youcai, Chairman and General Manager, reflected on eight years of hard work, acknowledged the team’s achievements, and shared his vision for the future. He emphasized that "only through innovation can we go far" and urged the team to stay committed to the five-year strategic goals, strive for progress, and jointly build a stronger line of defense for global health.
The official launch of Huierkangxin will provide society with a more advanced, safer, and more effective influenza vaccination option, reduce vaccine hesitancy, further increase the influenza vaccination rate, and contribute to China’s influenza prevention and control efforts.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
